Den europeiske union - norsk - EMA (European Medicines Agency)

roche registration gmbh - trastuzumab emtansin - bryst neoplasms - antineoplastiske midler - tidlig brystkreft (ebc)kadcyla, som en enkelt agent, er indikert for adjuvant behandling av voksne pasienter med her2-positiv tidlig brystkreft som har rester av invasiv sykdom i bryst og/eller lymfeknuter, etter neoadjuvant taxane-basert og her2-rettet behandling. metastatisk brystkreft (mbc)kadcyla, som en enkelt agent, er indisert for behandling av voksne pasienter med her2-positiv, inoperabel lokalt avansert eller metastatisk brystkreft som tidligere har fått trastuzumab og en taxane, hver for seg eller i kombinasjon. pasienter bør ha enten:mottatt før behandling for lokalt avansert eller metastatisk sykdom, ordeveloped sykdom tilbakefall under eller innen seks måneder etter at du har fullført adjuvant behandling.

Den europeiske union - norsk - EMA (European Medicines Agency)

ptc therapeutics international limited - eladocagene exuparvovec - aminosyre-metabolisme, infiserte feil - enzymes, other alimentary tract and metabolism products - upstaza is indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic l amino acid decarboxylase (aadc) deficiency with a severe phenotype (see section 5.

Norge - norsk - Statens legemiddelverk

orion corporation - espoo - rivastigminhydrogentartrat - kapsel, hard - 3 mg

Norge - norsk - Statens legemiddelverk

orion corporation - espoo - rivastigminhydrogentartrat - kapsel, hard - 1.5 mg

Norge - norsk - Statens legemiddelverk

orion corporation - espoo - rivastigminhydrogentartrat - kapsel, hard - 4.5 mg

Norge - norsk - Statens legemiddelverk

orion corporation - espoo - rivastigminhydrogentartrat - kapsel, hard - 6 mg

Den europeiske union - norsk - EMA (European Medicines Agency)

accord healthcare s.l.u. - memantinhydroklorid - alzheimers sykdom - andre anti-demens medisiner - behandling av pasienter med moderat til alvorlig alzheimers sykdom.

Den europeiske union - norsk - EMA (European Medicines Agency)

takeda pharma a/s - brentuximab vedotin - lymphoma, non-hodgkin; hodgkin disease - antineoplastiske midler - hodgkin lymphomaadcetris is indicated for adult patients with previously untreated cd30+ stage iv hodgkin lymphoma (hl) in combination with doxorubicin, vinblastine and dacarbazine (avd). adcetris is indicated for the treatment of adult patients with cd30+ hl at increased risk of relapse or progression following autologous stem cell transplant (asct). adcetris is indicated for the treatment of adult patients with relapsed or refractory cd30+ hodgkin lymphoma (hl):following asct, orfollowing at least two prior therapies when asct or multi-agent chemotherapy is not a treatment option. systemic anaplastic large cell lymphomaadcetris in combination with cyclophosphamide, doxorubicin and prednisone (chp) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (salcl). adcetris is indicated for the treatment of adult patients with relapsed or refractory salcl. cutaneous t cell lymphomaadcetris is indicated for the treatment of adult patients with cd30+ cutaneous t cell lymphoma (ctcl) after at least 1 prior systemic therapy.

Norge - norsk - Statens legemiddelverk

teva pharma b.v. (4) - tenofovirdisoproksilfumarat - tablett, filmdrasjert - 245 mg

Norge - norsk - Statens legemiddelverk

viatris limited - atovakvon / proguanilhydroklorid - tablett, filmdrasjert - 250 mg / 100 mg